| Metric | Q3'25 | Q4'25 | Change |
|---|---|---|---|
| Adjusted EPS | $1.84 (Q3) | -$2.75 (Q4) | Massive miss, $4.59 swing negative |
| Premium Revenue | $10.8B (Q3) | $10.7B (Q4) | Flat sequentially, up 11% YoY |
| Consolidated MCR | 92.6% (Q3) | Not disclosed (Q4) | Management stopped reporting consolidated Q4 MCR |
| Medicaid MCR | 92.0% (Q3) | 93.5% (Q4) | +150bp deterioration, 160bp from CA retros |
| Medicare MCR | 93.6% (Q3) | 97.5% (Q4) | +390bp blowup, LTSS and drugs |
| Marketplace MCR | 95.6% (Q3) | 99.0% (Q4) | +340bp deterioration, prior period settlements |
| Full Year Medicaid Trend | 6% then raised to 7% | 7.5% actual | +150bp vs initial, +50bp vs Q3 raise |
| 2026 EPS Guidance | $14 initial outlook (Q3) | At least $5 | 64% cut from Q3 outlook |
| Embedded Earnings | $8.65 (Q3) | $11+ per share | +$2.35 boost from Florida CMS |
| Operating Cash Flow (FY) | -$237M (9M) | -$535M (FY) | Negative $535M outflow vs positive historically |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.